--- title: "SpyGlass Pharma (SGP) news: IPO and lawsuit" url: "https://aibio.space/companies/spyglass-pharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SGP IPO and lawsuit news: SpyGlass ends June with $234.2 million and says cash lasts through 2028. SpyGlass Pharma, Inc. (NASDAQ: SGP), United States." --- SGP SpyGlass Pharma, Inc. NASDAQ · United States # SpyGlass Pharma (SGP) news SGP IPO and lawsuit news Mergers · 2026-10-01 ## [SpyGlass buys lens maker Advanced Vision Science from Santen for about $13 million](https://aibio.space/news/spyglass-buys-lens-maker-advanced-vision-science-santen-about-13/) The cash deal brings in house the company that makes the intraocular lens used in both of SpyGlass's Phase 3 glaucoma trials. The seller, Santen, gets an exclusive right to sell AVS's Eternity lenses in Japan. ## Latest SpyGlass Pharma news 1. 2026-08-06 Financings [SpyGlass ends June with $234.2 million and says cash lasts through 2028](https://aibio.space/news/spyglass-ends-june-234-2-million-says-cash-lasts-through-2028/) Second-quarter net loss was $19.9 million. SpyGlass says its IPO proceeds and cash will fund operations through 2028 and that it will need substantial additional funding after that. 2. 2026-05-22 Legal [SpyGlass countersues Glaukos in trade-secret case; trial moved to January 2027](https://aibio.space/news/spyglass-countersues-glaukos-trade-secret-case-trial-moved-january/) Defendants are SpyGlass Pharma and employee Long Doan. SpyGlass countersued Glaukos on May 22 over contract interference, and the court moved trial to January 2027. 3. 2026-02-09 Financings [SpyGlass closes $172.5 million IPO after underwriters take full option](https://aibio.space/news/spyglass-closes-172-5-million-ipo-after-underwriters-take-full-option/) SpyGlass Pharma closed a $172.5 million IPO with Jefferies, Leerink Partners, Citigroup and Stifel running the book. The money is meant to carry a glaucoma implant through two Phase 3 trials. ## SpyGlass Pharma at a glance - **Ticker**: SGP - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $223.1 million ### Related companies - [Nurix Therapeutics](https://aibio.space/companies/nurix-therapeutics/) NASDAQ: NRIX - [Vincerx Pharma](https://aibio.space/companies/vincerx-pharma/) OTC: VINC - [CalciMedica](https://aibio.space/companies/calcimedica/) NASDAQ: CALC - [NeOnc Technologies Holdings](https://aibio.space/companies/neonc-technologies/) NASDAQ: NTHI - [Axsome Therapeutics](https://aibio.space/companies/axsome-therapeutics/) NASDAQ: AXSM - [Iambic Therapeutics](https://aibio.space/companies/iambic-therapeutics/) NASDAQ: IAM - [Provectus Biopharmaceuticals](https://aibio.space/companies/provectus-biopharmaceuticals/) OTC: PVCT - [Revelation Biosciences](https://aibio.space/companies/revelation-biosciences/) NASDAQ: REVB ### Also on NASDAQ - [Entera Bio](https://aibio.space/companies/entera-bio/) ENTX - [Twist Bioscience](https://aibio.space/companies/twist-bioscience/) TWST - [ArriVent BioPharma](https://aibio.space/companies/arrivent-biopharma/) AVBP - [Decoy Therapeutics](https://aibio.space/companies/decoy-therapeutics/) DCOY - [Niagen Bioscience](https://aibio.space/companies/niagen-bioscience/) NAGE - [Kura Oncology](https://aibio.space/companies/kura-oncology/) KURA ## SpyGlass Pharma annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$29.2 million](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/) | [$20.0 million](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/) | | Net income (loss) | [-$39.9 million](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/) | [-$29.2 million](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/) | | Cash from operations | [-$32.7 million](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/) | [-$22.0 million](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/) | | Cash and equivalents | [$96.4 million](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000045/) | [$16.3 million](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $223.1 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about SpyGlass Pharma When did SpyGlass Pharma go public? Our latest story on this, dated Aug 6, 2026: "SpyGlass ends June with $234.2 million and says cash lasts through 2028". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/spyglass-ends-june-234-2-million-says-cash-lasts-through-2028/). Is SpyGlass Pharma involved in a lawsuit? Our latest story on this, dated May 22, 2026: "SpyGlass countersues Glaukos in trade-secret case; trial moved to January 2027". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/spyglass-countersues-glaukos-trade-secret-case-trial-moved-january/). What is the ticker symbol of SpyGlass Pharma? SpyGlass Pharma, Inc. trades under the ticker SGP on NASDAQ. Where is SpyGlass Pharma listed? SpyGlass Pharma, Inc. is listed on NASDAQ. What is the SEC CIK of SpyGlass Pharma? The SEC Central Index Key (CIK) for SpyGlass Pharma, Inc. is 1778922. Its filings are on SEC EDGAR. How many shares does SpyGlass Pharma have outstanding? 33,447,979 shares as of 2026-07-29, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is SpyGlass Pharma listed under? Our directory records SpyGlass Pharma, Inc. under United States. What does SpyGlass Pharma do? Our directory classifies SpyGlass Pharma, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of SpyGlass Pharma? The ISIN recorded for SpyGlass Pharma, Inc. is US85220G1094. Does aibio.space cover SpyGlass Pharma? aibio.space lists SpyGlass Pharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is SpyGlass Pharma incorporated? SEC records list its state or country of incorporation as DE. Is SpyGlass Pharma profitable? SpyGlass Pharma, Inc. reported a net loss of $39.9 million for the fiscal year ended Dec 31, 2025, and used $32.7 million of cash in operations, per its annual report to the SEC. How much does SpyGlass Pharma spend on research and development? $29.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does SpyGlass Pharma have? $223.1 million in cash at Jun 30, 2026, per its 10-Q. What is the latest SpyGlass Pharma (SGP) stock news? Our latest story on SpyGlass Pharma, dated Oct 1, 2026: "SpyGlass buys lens maker Advanced Vision Science from Santen for about $13 million". The cash deal brings in house the company that makes the intraocular lens used in both of SpyGlass's Phase 3 glaucoma trials. The seller, Santen, gets an exclusive right to sell AVS's Eternity lenses in Japan. [Source](https://aibio.space/news/spyglass-buys-lens-maker-advanced-vision-science-santen-about-13/). ## Investor discussion: SpyGlass Pharma Members talk about SpyGlass Pharma (SGP). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at SpyGlass Pharma, newest first. Each line links the filing it comes from. 1. 2026-10-01 Merger SpyGlass closed the acquisition of its lens supplier for a $13 million base purchase price subject to adjustments. [Source](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000049/sgp-20261001.htm) 2. 2026-03-26 Financing The annual report disclosed the March 2025 Series C-2 closing of approximately $50 million; no exact closing day is supplied. [Source](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/sgp-20251231.htm) 3. 2026-02-09 Financing The IPO closed with the underwriters option fully exercised. [Source](https://www.sec.gov/Archives/edgar/data/1778922/000162828026006460/exhibit991-closing8xk.htm) 4. 2026-02-06 Financings Reported a financing. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1778922/000162828026006068/spyglass-424b4.htm) 5. 2026-02-05 Leadership Habib Dable joined the board in connection with the IPO. [Source](https://www.sec.gov/Archives/edgar/data/1778922/000162828026006460/spyglassclosing8-k.htm) 6. 2026-01-28 Reverse split SpyGlass implemented a one-for-5.7329 reverse split before its IPO. [Source](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000045/sgp-20260630.htm) 7. 2026-01-16 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1778922/000162828026002356/spyglass-sx1.htm) 8. 2025-06-05 Financing SpyGlass filed a private-offering notice reporting $74,999,989 sold. [Source](https://www.sec.gov/Archives/edgar/data/1778922/000177892225000001/xslFormDX01/primary_doc.xml) 9. 2025-05-30 Financing The private-offering notice identifies the first sale date; its reported total is dated to that notice. [Source](https://www.sec.gov/Archives/edgar/data/1778922/000177892225000001/xslFormDX01/primary_doc.xml) ## Investor questions about SpyGlass Pharma ### How much liquidity did the latest quarter report? At 2026-06-30, SpyGlass reported $223.143 million cash and equivalents and $11.043 million short-term investments. These are dated financial-statement balances. Source ### What funding horizon did management project? The quarterly report projected operating-expense and capital-expenditure funding through 2028. It is a management forecast, not a guaranteed cash exhaustion date. Source ### Did the latest report state unresolved substantial doubt? No substantial-doubt statement was found in the opened quarterly report. Management instead states sufficient liquidity for the next twelve months, while acknowledging future financing risks. Source ### How much did the IPO raise? The completed IPO produced $172.5 million gross, including the full underwriters option, before underwriting and other offering costs. Source ### Did SGP implement a reverse split? A one-for-5.7329 split became effective on 2026-01-28 before the IPO. The source describes a capitalization adjustment, not an exchange deficiency cure. Source ### What business did SpyGlass acquire? The company acquired all outstanding equity of Advanced Vision Science, Inc., its existing lens supplier. The base price was $13 million, subject to closing adjustments. Source ### Is the Glaukos matter a securities class action? The disclosed case concerns trade-secret and related claims against SpyGlass and an employee, not a disclosed shareholder class action. SpyGlass denies the allegations and has filed counterclaims. Source ### What trial date does the quarterly report identify? The report states that the original trial date was extended to 2027-01-26. No current docket confirmation of that date was obtained. Source ### Does the employee-plan registration represent a new cash raise? No. It covers shares subject to awards or reserved for future plan issuance, rather than announcing completed investor subscriptions. Source ### Can affiliated Form 4 purchases be added together? No. Fund and control-person reports can describe the same underlying purchase. The annual ownership table likewise attributes overlapping interests to affiliated directors. Source ### Who signed the latest annual audit? Deloitte & Touche LLP signed the annual audit and states service since 2025. No complete earlier auditor-change chronology was verified. Source ### Has an open Nasdaq deficiency been verified? The IPO closing release identifies the Nasdaq Global Select Market. Source ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SGP on TradingView](https://www.tradingview.com/symbols/NASDAQ-SGP/). ## SEC filings and registration - **SEC name**: SpyGlass Pharma, Inc. - **CIK**: 1778922 - **Industry (SIC)**: Surgical & Medical Instruments & Apparatus (3841) - **US tickers**: SGP (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 15326 ALTON PARKWAY, IRVINE, CA, 92618 - **Phone**: 949-284-6904 - **Shares outstanding**: 33,447,979 as of 2026-07-29 (10-Q filed 2026-08-06) - **Former names**: SpyGlassPharma, Inc.; SpyGlass Ophthalmics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000052/sgp-20261019.htm) filed 2026-10-19 - [8-K](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000049/sgp-20261001.htm) filed 2026-10-01 - [10-Q](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000045/sgp-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000044/sgp-20260806.htm) filed 2026-08-06 - [10-Q](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000035/sgp-20260331.htm) filed 2026-05-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000033/sgp-20260514.htm) filed 2026-05-14 - [10-K](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/sgp-20251231.htm) filed 2026-03-26 - [8-K](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000018/sgp-20260326.htm) filed 2026-03-26 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001778922), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details SpyGlass Pharma, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SGP, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: SpyGlass Pharma, Inc. - **Ticker**: SGP - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US85220G1094 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SGP/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/spyglass-pharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "SpyGlass Pharma (SGP) news: IPO and lawsuit", 2026-10-31, https://aibio.space/companies/spyglass-pharma/